Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gilead misses key goal in NASH liver disease trial, shares sink

Gilead Sciences Inc. said a late-stage study for selonsertib aimed at treating the progressive fatty liver disease NASH failed to meet the key experimental drug’s main goal, sending the company’s shares down 4.6 percent.

Read More »

Sangamo shares dive after poor early-stage trial data

Sangamo Therapeutics Inc.’s shares sank 27 percent after the company’s gene-editing drug failed to show promise in an early-stage trial testing for patients with ultra-rare disorders.

Read More »

Eli Lilly backs U.S. proposal on drug rebates to lower costs

Eli Lilly embraced a U.S. government proposal to end a decades-old system of rebates drugmakers make to industry middlemen.

Read More »

Argenx and Halozyme Ink Multiple Target Deal

Argenx and Halozyme Therapeutics signed a global collaboration and license deal that allows Argenx to use Halozyme’s Enhanze drug delivery technology to develop multiple products.

Read More »

Merck’s Keytruda tops $2 billion in Q4 2018 sales

Merck & Co.’s cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street’s lofty estimates and sending the company’s shares up.

Read More »

Novo Nordisk’s new diabetes drug, outlook lift shares

Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.

Read More »

Celgene Q4 2018 profit beats forecast

Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.

Read More »

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc. reported fourth-quarter 2018 profit that easily surpassed expectations as sales rose and tax expense fell, but competition for the company’s older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Read More »

Botox maker Allergan’s 2018 revenue forecast misses estimates, shares drop

Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.

Read More »

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom